IP Library › Granted Patent US 11,730,827
Granted Patent B2
US 11,730,827 · App. 16/483,668 · Granted Aug 22, 2023

Materials and methods for delivering nucleic acids to cochlear and vestibular cells

Inventors: Jeffrey Holt (Boston, MA); Gwenaelle Geleoc (Boston, MA); Yukako Asai (Boston, MA)
Assignee: CHILDREN'S MEDICAL CENTER CORPORATION
A61K48/0058A61P27/16C07K14/4716C07K14/705C12N15/86C07H21/04
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 11,730,827
App. No.
16/483,668
Granted
Aug 22, 2023
Kind
B2
Abstract

Provided herein are materials and methods for efficiently delivering nucleic acids to cochlear and vestibular cells, and methods of treating sensory transduction disorders associated with a genetic defect. Some embodiments are directed to a synthetic inner ear hair cell targeting adeno-associated virus (AAV) vector, a cell comprising the synthetic inner ear hair cell targeting AAV vector, and method of treating Usher Syndrome in a subject using the synthetic inner ear hair cell targeting AAV vector.

Claims (16)

1. A method of restoring hearing function and vestibular function in a subject with a hearing disorder or vestibular disorder, the method comprising:

injecting to inner ear cells of the subject, a synthetic inner ear hair cell targeting adeno-associated virus (AAV) vector,

wherein the vector:

encodes a capsid having at least 85% sequence identity to Anc80 of SEQ ID NO:1,

comprises a promoter selected from the group consisting of an Espin promoter, a protocadherin 15 (PCDH15) promoter, a protein tyrosine phosphatase receptor type Q (PTPRQ) promoter, and a tetraspan membrane protein of hair cell stereocilia (TMHS) (lipoma HMGIC fusion partner-like 5, LHFPL5) promoter, and

comprises a polynucleotide,

wherein the promoter directs expression of the polynucleotide encoding transmembrane channel-like 1 (TMC1),

thereby restoring hearing function and vestibular function in the subject.

2. The method of claim 1 , wherein the administering reverses hearing loss.

3. The method of claim 2 , wherein the hearing loss is partial hearing loss or complete deafness.

4. The method of claim 2 , wherein recovery of hearing function is associated with preservation of hair bundle morphology and/or restoration of mechanotransduction.

5. The method of claim 1 , wherein the subject with the hearing disorder or vestibular disorder suffers from Usher syndrome.

6. The method of claim 1 , wherein the injecting occurs through a round window membrane.

7. The method of claim 1 , wherein the AAV vector is AAV1 or AAV2.

8. The method of claim 1 , wherein the AAV vector is AAV1.

9. The method of claim 1 , wherein the AAV vector encodes the Anc80 capsid of SEQ ID NO:1.

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Aug 7, 2019
From: HOLT, JEFFREY; GELEOC, GWENAELLE; ASAI, YUKAKO
To: CHILDREN'S MEDICAL CENTER CORPORATION
Reel/Frame 049993/0242 →
Continuity (2)
Provisional Application 62455197 · Feb 6, 2017
Related Publication 20190351072A1 · Nov 21, 2019
Cited By (2)
US 12,281,313 US 12,612,645